c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

Alessandra Di BaccoNizar J BahlisNikhil C MunshiHervé Avet-LoiseauTamás MassziLuísa ViterboLudek PourPeter GanlyMichele CavoChristian LangerShaji K KumarS Vincent RajkumarJonathan J KeatsDeborah BergJianchang LinBin LiSunita BadolaLei ShenJacob ZhangDixie-Lee EsseltineKatarina LuptakovaHelgi van de VeldePaul G RichardsonPhillipe Moreau

Published in: European journal of haematology (2020)

PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c-MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE-MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537.

Keyphrases

multiple myeloma
poor prognosis
newly diagnosed
clinical trial
stem cell transplantation
low dose
high dose
binding protein
long non coding rna
phase iii
risk assessment
phase ii
open label